. Author manuscript; available in PMC: 2023 Feb 21.

Published in final edited form as: Diabetes Obes Metab. 2020 Dec 21;23(3):730–741. doi: 10.1111/dom.14278

Table 1.

Descriptive characteristics at baseline (unless otherwise noted) by study centre. ADDITION-Europe 2002-2014

	Total (N=3057)				Denmark (N= 1533)				Cambridge (N=867)				Leicester (N=159)				Netherlands (N=498)
Characteristic	Total	Mean	SD		n	Mean	SD		Mean	n	SD		n	Mean	SD		n	Mean	SD
Age at diagnosis	3057	60.2	6.9		1533	59.9	6.9		867	61.1	7.1		159	57.7	8.0		498	60.5	5.2
BMI (kg/m²)	2957	31.6	5.6		1450	30.8	5.4		861	33.5	5.7		156	30.8	5.4		490	30.9	5.2
Weight (kg)	2959	90.6	17.6		1450	89.2	17.6		863	94.4	17.8		156	85.8	17.1		490	89.5	16.1
Weight at 1yr (kg)	1221	89.3	17.5		--	--	--		733	91.2	17.7		151	84.6	19.0		337	87.4	15.7
Change weight 0-1yr	1209	-3.3	6.4		--	--	--		730	-3.6	5.5		148	-2.2	5.9		331	-3.1	8.2
Percent change in weight 0-1yr (%)	1209	-3.5	6.7		--	--	--		730	-3.7	5.7		148	-2.7	6.0		331	-3.2	8.7
Weight at 5yr (kg	2683	88.8	18.0		1326	88.5	18.0		773	90.5	18.3		139	83.1	18.3		445	88.4	17.0
Change weight 0-5yr	2611	-2.1	7.4		1266	-1.1	7.1		770	-4.0	7.3		137	-3.0	6.4		438	-1.4	7.7
Percent change in weight 0-5yr (%)	2611	-2.2	7.8		1266	-1.1	7.7		770	-4.1	7.5		137	-3.5	7.1		438	-1.5	8.2
Alcohol (units/week)	2675	9	12		1372	10	11		853	8	12		90	11	9		360	9	16
Systolic BP (mmHg)	2963	149	22		1451	148	20		865	142	20		158	146	17		489	165	23
Diastolic BP (mmHg)	2964	86	11		1451	88	11		865	82	10		158	89	10		490	89	11
Total cholesterol (mmol/1)	2893	5.6	1.1		1410	5.6	1.1		848	5.4	1.1		159	5.6	1.2		476	5.6	1.1
LDL-cholesterol (mmol/l)	2749	3.4	1.0		1324	3.4	1.0		817	3.3	1.0		142	3.5	1.0		466	3.7	1.0
Observed time at risk for events (years)	2730	5.0	1.1		1363	4.9	1.0		777	5.1	1.2		140	5.1	0.7		450	4.9	1.0
	n	Med.	Q1	Q3	n	Med.	Q1	Q3	n	Med	Q1	Q3	n	Med.	Q1	Q3	n	Med.	Q1	Q3
HbA_1c (%)	2889	6.6	6.1	7.3	1477	6.4	6.0	7.0	846	6.8	6.4	7.6	159	6.8	6.4	7.6	407	6.8	6.3	7.6
HbA_1c (mmol/mol)	2889	48.6	43.2	56.3	1477	46.4	42.1	53.0	846	50.8	45.4	60.7	159	50.8	46.4	59.6	407	50.8	45.4	59.6
Triglycerides (mmol/L)	2874	1.7	1.2	2.4	1391	1.6	1.1	2.3	847	1.8	1.1	2.5	159	1.8	1.1	2.5	477	1.6	1.2	2.4
	Total n	%	n		Total n	%	n		N	%	n		N	%	n		N	%	n
Sex
Women	3057	42	1286		1533	43	660		867	39	337		159	37	59		498	46	230
Smoking
Current	2996	27	819		1513	34	518		865	18	158		159	16	25		459	26	118
Former	2996	40	1200		1513	37	554		865	44	383		159	27	43		459	48	220
Never	2996	33	977		1513	29	441		865	37	324		159	57	91		459	26	121
Medication use prior to diabetes diagnosis
Antihypertensive	2949	45	1337		1466	43	634		865	58	499		159	42	67		459	30	137
Lipid-lowering	2949	16	480		1466	13	185		865	24	204		159	21	34		459	12	57
Left full-time education ≤16 years old	2154	42	899		1039	13	131		657	72	474		139	65	91		319	64	203
History of CVD prior to diabetes diagnosis	2857	9	243		1460	8	112		855	12	99		104	7	7		438	6	25
Incident CVD events^†	2730	8	229		1363	8	114		777	10	75		140	6	8		450	13	32
Incident all-cause mortality^‡	2706	8	225		1353	9	119		766	9	69		140	2	3		447	8	34

^†

Incident CVD events are defined as first event occurring during the follow-up period, beginning 5 years after diabetes diagnosis

^‡

Incident all-cause mortality events exclude events occurring in the first year of the follow-up period, therefore follow-up for all-cause mortality begins 6 years after diabetes diagnosis.